Article Text

Download PDFPDF
CASE REPORT
Is it safe to acutely discontinue insulin therapy in patients with chronic hyperglycaemia starting GLP-1R agonists?
  1. Julie Omolola Okiro1,
  2. Catherine Mc Hugh2,
  3. Abuelmagd Abdalla3
  1. 1Sligo University Hospital, Sligo, Ireland
  2. 2Department of Medicine, Sligo University Hospital, Sligo, Ireland
  3. 3Department of Endocrinology, Sligo General Hospital, Sligo, Ireland
  1. Correspondence to Dr Julie Omolola Okiro, Julieokiro{at}gmail.com

Summary

We report two patients with chronic hyperglycaemia secondary to type 2 diabetes who developed severe vomiting on d. The first patient was diagnosed with a mixed picture of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS) and the second, with DKA. They were on insulin therapy which was discontinued on commencing d because of inefficacy and weight gain. The HHS patient developed dehydration secondary to vomiting and had lactic acidosis but no other precipitant could be found in either case. It appears that the abrupt insulin discontinuation coupled with vomiting and dehydration led to the metabolic derangements. Subsequent C-peptide levels were found to be low in both patients. In view of the predisposition of patients with chronic hyperglycaemia to glucagon-like peptide 1 receptor (GLP-1R) downregulation and the lag time to optimal efficacy of GLP-1R agonists, we propose that patients should have C-peptide levels measured to determine the risk of ketosis and whether insulin should be continued with dose adjustments when starting a GLP-1R agonist.

  • Diabetes
  • Drugs: endocrine system

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors JOO and CMH are both first authors. JOO contributed in writing summary, background, case presentation, investigations, discussion and learning point. CMH oversaw the preparation of this article and contributed in writing summary, background, differential diagnosis, outcome, discussion and learning point. AA contributed in writing background, case presentation, differential diagnosis, discussion and referencing.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.